News & Updates

Use of rituximab, temozolomide, and radiation appears safe and effective as salvage therapy for patients with recurrent or refractory primary central nervous system (CNS) lymphoma, according to a study in the Philippines, the results of which were presented at the recent AAN 2023.

Use of vitamin D but not calcium supplementation appears effective at preventing multiple sclerosis (MS) in individuals of European descent, suggests a recent study.

Motivational interviewing (MI) in combination with cognitive behavioural therapy (CBT) improves negative symptoms in patients with schizophrenia, reports a study. These symptoms are initially thought of as resistant to any intervention.

The first study to directly compare two disease-modifying agents for Alzheimer’s disease (AD), the phase III TRAILBLAZER-ALZ 4 study shows promising efficacy and safety data on donanemab vs aducanumab for the treatment of early symptomatic AD.

Treatment with zavegepant nasal spray provides pain and symptom relief in patients with migraine, according to a recent US study presented at AAN 2023.

A cross-sectional study from the Chinese University of Hong Kong suggests that Parkinson’s disease (PD)–like gut dysbiosis occurs at preclinical prodromal stages of PD, in patients with video-polysomnography (v-PSG)–confirmed REM sleep behavior disorder (RBD) and even in their younger first-degree relatives (RBD-FDR).